- Home
- AGMB vs THFF Comparison
AGMB vs THFF Comparison
Compare AGMB & THFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGMB | THFF |
|---|---|---|
| Founded | 2017 | 1984 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 677.9M | 796.4M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | AGMB | THFF |
|---|---|---|
| Price | $11.86 | $65.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $32.00 | ★ $62.00 |
| AVG Volume (30 Days) | ★ 137.3K | 67.2K |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | N/A | ★ 67.00 |
| EPS | N/A | ★ 6.68 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.88 |
| Revenue Next Year | $17.86 | $4.03 |
| P/E Ratio | ★ N/A | $9.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.00 | $49.70 |
| 52 Week High | $17.45 | $69.21 |
Technical Indicators
Market Signals| Indicator | AGMB | THFF |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 49.77 |
| Support Level | $10.30 | $64.80 |
| Resistance Level | $12.21 | $66.70 |
| Average True Range (ATR) | 0.84 | 1.72 |
| MACD | 0.21 | -0.20 |
| Stochastic Oscillator | 68.15 | 28.37 |
Price Performance
Historical ComparisonAbout AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.